Magnussen 2007.

Methods	STUDY DESIGN: Parallel group LOCATION, NUMBER OF CENTRES: Europe, number of centres not reported DURATION OF STUDY: 12 weeks (1‐4 weeks prn SABA) CONCEALMENT OF ALLOCATION: Unclear COCHRANE QUALITY SCORE: B DESCRIBED AS RANDOMISED: Yes DESCRIBED AS DOUBLE BLIND: Yes METHOD OF RANDOMISATION WELL DESCRIBED/APPROPRIATE: Not reported METHOD OF BLINDING WELL DESCRIBED/APPROPRIATE: Both treatments given via MDIs DESCRIPTION OF WITHDRAWALS/DROPOUTS: Stated JADAD SCORE (5‐1): 4 TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT and PP COMPLIANCE: Not reported CONFOUNDERS: Balanced groups at baseline
Participants	N SCREENED: Not reported N RANDOMISED: 808 N COMPLETED: 764 M = 409; F = 398 MEDIAN AGE: 29‐33 BASELINE DETAILS: FEV1 predicted: 79%; reversibility: 25% INCLUSION CRITERIA: ATS defined asthma; 12‐75 years; 61‐90% predicted (if treated with ICS), or 61‐105% predicted if not treated with ICS; maximum daily dose was FP 250 mcg; post‐run in participants had to demonstrate FEV1 between 60‐90% predicted. EXCLUSION: Concomitant severe disease; smoking history of >10 pack years; LABA or OCS treatment in previous 4 weeks.
Interventions	1. Ciclesonide 100 mcg OD 2. Ciclesonide 200 mcg OD 3. Fluticasone 100 mcg BID DELIVERY: MDI TREATMENT PERIOD: 12 weeks RESCUE: Salbutamol CO‐INTERVENTIONS PERMITTED: Not reported CO‐INTERVENTIONS: Not reported % on ICS: Not reported
Outcomes	FEV1; peak flow; asthma symptoms; asthma exacerbations requiring oral steroids
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear